144 related articles for article (PubMed ID: 10489124)
1. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.
Sugo H; Takamori S; Kojima K; Beppu T; Futagawa S
Surg Today; 1999; 29(9):849-55. PubMed ID: 10489124
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.
Hayashi H; Sugio K; Matsumata T; Adachi E; Takenaka K; Sugimachi K
Hepatology; 1995 Dec; 22(6):1702-7. PubMed ID: 7489977
[TBL] [Abstract][Full Text] [Related]
3. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?
Sheen IS; Jeng KS; Wu JY
World J Gastroenterol; 2003 Jun; 9(6):1202-7. PubMed ID: 12800224
[TBL] [Abstract][Full Text] [Related]
4. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma.
Park NH; Chung YH; Youn KH; Song BC; Yang SH; Kim JA; Lee HC; Yu E; Lee YS; Lee SG; Kim KW; Suh DJ
J Clin Gastroenterol; 2001; 33(5):397-401. PubMed ID: 11606857
[TBL] [Abstract][Full Text] [Related]
5. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.
Yano M; Hamatani K; Eguchi H; Hirai Y; MacPhee DG; Sugino K; Dohi K; Itamoto T; Asahara T
Eur J Cancer; 2007 Apr; 43(6):1092-100. PubMed ID: 17350822
[TBL] [Abstract][Full Text] [Related]
6. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
Honda K; Sbisà E; Tullo A; Papeo PA; Saccone C; Poole S; Pignatelli M; Mitry RR; Ding S; Isla A; Davies A; Habib NA
Br J Cancer; 1998 Mar; 77(5):776-82. PubMed ID: 9514057
[TBL] [Abstract][Full Text] [Related]
7. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
8. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
9. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
10. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
[TBL] [Abstract][Full Text] [Related]
12. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
13. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
14. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of p53 mutations in primary and secondary liver tumors: diagnostic and therapeutic perspectives.
Tullo A; Sbisà E
Mol Biotechnol; 2002 Jul; 21(3):265-78. PubMed ID: 12102551
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.
Ko E; Kim Y; Kim SJ; Joh JW; Song S; Park CK; Park J; Kim DH
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830
[TBL] [Abstract][Full Text] [Related]
18. S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors.
Yuan RH; Chang KT; Chen YL; Hsu HC; Lee PH; Lai PL; Jeng YM
PLoS One; 2013; 8(6):e65501. PubMed ID: 23785431
[TBL] [Abstract][Full Text] [Related]
19. Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation.
Gross-Goupil M; Riou P; Emile JF; Saffroy R; Azoulay D; Lacherade I; Receveur A; Piatier-Tonneau D; Castaing D; Debuire B; Lemoine A
Int J Cancer; 2003 May; 104(6):745-51. PubMed ID: 12640682
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma.
Shiota G; Kishimoto Y; Suyama A; Okubo M; Katayama S; Harada K; Ishida M; Hori K; Suou T; Kawasaki H
J Hepatol; 1997 Oct; 27(4):661-8. PubMed ID: 9365042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]